Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2 - Annunziata, C M; Walker, A J; Minasian, L (Clin Cancer Res, 2010)
et al.